-
CDK9-IN-7
- names:
CDK9-IN-7
- CAS号:
2369981-71-3
MDL Number: - MF(分子式): C29H37N7O2S MW(分子量): 547.71
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM001512-250mg | 250mg | ¥ 0.00 | ¥ 0.00 | Backorder | ¥ 0.00 | |||
| YZM001512-100mg | 100mg | >97% | ¥ 0.00 | ¥ 0.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | |
| CAS号 | 2369981-71-3 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C29H37N7O2S |
| 分子量 Molecular Weight | 547.71 |
| 溶解度Solubility | |
| 性状 | |
| 储藏条件 Storage conditions | 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description. |
CDK9-IN-7(CAS:2369981-71-3)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | CDK9-IN-7 (compound 21e) 是一种有效的高效选择性的,具有口服活性的CDK9/cyclin T抑制剂 (IC50=11 nM),与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM) |
| Introduction | CDK9N (compound 21e) is a selective, highly potent, and orally activeCDK9/cyclin Tinhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9N shows antitumor activity without obvious toxicity. CDK9N induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC. |
| Application1 | |
| Application2 | |
| Application3 |
CDK9-IN-7 (compound 21e) 是一种有效的高效选择性的,具有口服活性的CDK9/cyclin T抑制剂 (IC50=11 nM),与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡,在 G2 期阻滞细胞周期,并具有抑制非小细胞肺癌干度的特性。CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally activeCDK9/cyclin Tinhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC[1].
【1】.Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


